https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-15 / Gene Ther. 2008 Oct;15(19):1321-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-15 / Gene Ther. 2008 Oct;15(19):1321-92008-05-15 00:00:002019-02-15 09:19:21Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-15 / Cancer Res. 2008 May;68(10):3854-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-15 / Cancer Res. 2008 May;68(10):3854-622008-05-15 00:00:002008-05-15 00:00:00Cancer immunotherapy using in vitro genetically modified targeted dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / Eur. J. Immunol. 2008 May;38(5):1310-20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / Eur. J. Immunol. 2008 May;38(5):1310-202008-05-01 00:00:002019-02-15 09:15:05Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / J. Immunother. 2008 May;31(4):345-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / J. Immunother. 2008 May;31(4):345-582008-05-01 00:00:002019-02-15 09:19:30Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / J. Immunother. 2008 May;31(4):402-12
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / J. Immunother. 2008 May;31(4):402-122008-05-01 00:00:002019-02-15 09:19:31Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / Rev Recent Clin Trials 2008 May;3(2):121-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / Rev Recent Clin Trials 2008 May;3(2):121-52008-05-01 00:00:002019-02-15 09:23:43Immunotherapy of pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-24 / Vaccine 2008 Jun;26(27-28):3540-92008-04-24 00:00:002019-02-15 08:49:58Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-21 / J. Leukoc. Biol. 2008 Jul;84(1):319-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-21 / J. Leukoc. Biol. 2008 Jul;84(1):319-252008-04-21 00:00:002019-02-15 08:37:26Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-15 / Int. J. Cancer 2008 Apr;122(8):1794-802
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-15 / Int. J. Cancer 2008 Apr;122(8):1794-8022008-04-15 00:00:002019-02-15 08:59:45Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-04-09 / Trends Mol Med 2008 May;14(5):228-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-04-09 / Trends Mol Med 2008 May;14(5):228-352008-04-09 00:00:002019-02-15 08:46:53Cell- and peptide-based immunotherapeutic approaches for glioma
